KIA
TEVA icon

King Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

King Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-60,845
Closed -$3.79M – 96
2015
Q1 		$3.79M Sell
60,845
-47,645
-44% -$2.77M 1.8% 23
2014
Q4 		$6.25M Sell
108,490
-565
-0.5% -$31.5K 2.79% 14
2014
Q3 		$5.86M Sell
109,055
-4,275
-4% -$226K 2.67% 14
2014
Q2 		$5.94M Sell
113,330
-2,298
-2% -$117K 2.53% 16
2014
Q1 		$6.11M Sell
115,628
-280
-0.2% -$12.9K 2.8% 10
2013
Q4 		$4.65M Buy
115,908
+81,737
+239% +$3.22M 2.12% 18
2013
Q3 		$1.29M Buy
34,171
+360
+1% +$14K 0.56% 47
2013
Q2 		$1.32M Buy
+33,811
New +$1.32M 0.55% 45

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

King Investment Advisors's TEVA Position: Q2 2015 in Review

King Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 60,845 shares — an estimated $3.79M sold.

King Investment Advisors first reported a position in TEVA in Q2 2013 and held it in 8 quarters. The position peaked at $6.25M in Q4 2014. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

  • King Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • King Investment Advisors sold 60,845 Teva Pharmaceuticals shares in Q2 2015, an estimated $3.79M.
  • King Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • King Investment Advisors's Teva Pharmaceuticals position peaked at $6.25M in Q4 2014.
  • 818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on King Investment Advisors's 13F filing for Q2 2015, filed 2 Nov 2015.